



# HOKKAIDO UNIVERSITY

Title	Influenza A Virus Can Undergo Multiple Cycles of Replication without M2 Ion Channel Activity
Author(s)	Watanabe, Tokiko; Watanabe, Shinji; Ito, Hiroshi et al.
Citation	Journal of Virology, 75(12), 5656-5662 <a href="https://doi.org/10.1128/JVI.75.12.5656-5662.2001">https://doi.org/10.1128/JVI.75.12.5656-5662.2001</a>
Issue Date	2001-06
Doc URL	<a href="https://hdl.handle.net/2115/28144">https://hdl.handle.net/2115/28144</a>
Rights	Copyright © 2001 American Society for Microbiology
Type	journal article
File Information	JV75-12.pdf



# Influenza A Virus Can Undergo Multiple Cycles of Replication without M2 Ion Channel Activity

TOKIKO WATANABE,<sup>1,2</sup> SHINJI WATANABE,<sup>1</sup> HIROSHI ITO,<sup>1</sup> HIROSHI KIDA,<sup>2</sup>  
AND YOSHIHIRO KAWAOKA<sup>1,3\*</sup>

*Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, Wisconsin 53706,<sup>1</sup> and Department of Disease Control, Graduate School of Veterinary Medicine, Hokkaido University, Sapporo 060-0818,<sup>2</sup> and Institute of Medical Science, University of Tokyo, Minato-ku, Tokyo 108-8639,<sup>3</sup> Japan*

Received 29 December 2000/Accepted 21 March 2001

**Ion channel proteins are common constituents of cells and have even been identified in some viruses. For example, the M2 protein of influenza A virus has proton ion channel activity that is thought to play an important role in viral replication. Because direct support for this function is lacking, we attempted to generate viruses with defective M2 ion channel activity. Unexpectedly, mutants with apparent loss of M2 ion channel activity by an in vitro assay replicated as efficiently as the wild-type virus in cell culture. We also generated a chimeric mutant containing an M2 protein whose transmembrane domain was replaced with that from the hemagglutinin glycoprotein. This virus replicated reasonably well in cell culture but showed no growth in mice. Finally, a mutant lacking both the transmembrane and cytoplasmic domains of M2 protein grew poorly in cell culture and showed no growth in mice. Thus, influenza A virus can undergo multiple cycles of replication without the M2 transmembrane domain responsible for ion channel activity, although this activity promotes efficient viral replication.**

Cell membranes consist of a double layer of lipid molecules in which various proteins are embedded. Because of its hydrophobic interior, the lipid bilayer of a cell membrane serves as a barrier to the passage of most polar molecules and therefore is crucial to cell viability. To facilitate the transport of small water-soluble molecules into and out of cells and intracellular compartments, such membranes possess carrier and channel proteins. Ion channels are essential for many cellular functions, including the electrical excitability of muscle cells and electrical signaling in the nervous system (1). They are present not only in all animal and plant cells and microorganisms, but have also been identified in viruses (12, 31, 32, 33, 37, 43, 44, 45), in which they are thought to play an important role in replication.

The influenza A virus is an enveloped negative-strand virus with eight RNA segments encapsidated with nucleoprotein (NP) (24). Spanning the viral membrane are three proteins: hemagglutinin (HA), neuraminidase (NA), and M2. The life cycle of viruses generally involves attachment to cell surface receptors, entry into the cell, and uncoating of the viral nucleic acid, followed by replication of the viral genes inside the cell. After the synthesis of new copies of viral proteins and genes, these components assemble into progeny virus particles, which then exit the cell (34). Different viral proteins participate in each of these steps. In influenza A viruses, the M2 protein, which possesses ion channel activity (32, 43, 44), is thought to function at an early stage in the viral life cycle, between host cell penetration and uncoating of viral RNA (16, 26, 44). Once virions have undergone endocytosis, the virion-associated M2 ion channel is believed to permit protons to flow from the

endosome into the virion interior to disrupt acid-labile M1 protein-ribonucleoprotein complex (RNP) interactions, thereby promoting RNP release into the cytoplasm (16). In addition, among some influenza virus strains whose HAs are cleaved intracellularly (e.g., A/fowl plague/Rostock/34 [FPV Rostock]), M2 ion channel activity is thought to raise the pH of the *trans*-Golgi network, preventing conformational changes in the HA due to conditions of low pH in this compartment (15, 29, 46).

Evidence that the M2 protein has ion channel activity was acquired by expressing the protein in oocytes of *Xenopus laevis* and measuring membrane currents (18, 32, 49). Specific changes in the M2 protein transmembrane (TM) domain altered the kinetics and ion selectivity of the channel, providing strong evidence that the M2 TM domain constitutes the pore of the ion channel (18). In fact, the M2 TM domain itself can function as an ion channel (10). Because a requirement for M2 ion channel activity in the replication of influenza A viruses has not been directly established, we generated a series of viruses with defective M2 ion channel activity using a recently established reverse-genetics system (13, 27) and tested their replication in cell culture and mice.

## MATERIALS AND METHODS

**Cells and viruses.** 293T human embryonic kidney cells and Madin-Darby canine kidney (MDCK) cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum (FCS) and in minimal essential medium (MEM) containing 5% newborn calf serum, respectively. The 293T cell line is a derivative of the 293 line into which the gene for the simian virus 40 T antigen was inserted (9). All cells were maintained at 37°C in 5% CO<sub>2</sub>. A/Udorn/307/72 (H3N2) virus was propagated in 10-day-old embryonated chicken eggs.

**Construction of plasmids.** The cDNA of Udorn virus was synthesized by reverse transcription of viral RNA with an oligonucleotide complementary to the conserved 3' end of viral RNA, as described by Katz et al. (21). The cDNA was amplified by PCR with M gene-specific oligonucleotide primers containing *Bsm*BI sites, and PCR products were cloned into the pT7Blueblunt vector (Novagen, Madison, Wis.). The resulting construct was designated pTPolIUdM.

\* Corresponding author. Mailing address: Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, 2015 Linden Drive West, Madison, WI 53706. Phone: (608) 265-4925. Fax: (608) 265-5622. E-mail: kawaokay@svm.vetmed.wisc.edu.




FIG. 1. Schematic diagram of mutant influenza virus M2 proteins and their properties. The amino acid sequence of the TM domain (residues 25 to 43) is shown in single-letter code in the expanded section of the diagram. Ion channel activity was determined by Holsinger et al. (18) using a two-electrode voltage clamp procedure. +, detectable ion channel activity; -, no detectable ion channel activity.

After digestion with *Bsm*BI, the fragment was cloned into the *Bsm*BI sites of the pHH21 vector, which contains the human RNA polymerase I promoter and the mouse RNA polymerase I terminator separated by *Bsm*BI sites, resulting in pPolIUdM. Plasmids derived from pHH21 for the expression of viral RNA (vRNA) are referred to as PolI constructs in this report.

The M mutants were constructed as follows. pTPolIUdM was first amplified by inverse PCR (28) using the back-to-back primers M2104R (5'-AAGAGGGT CACTTGAATCG-3') and M2V27T (5'-ACTGTTGCTGCGAGTATC-3'), M2A30P (5'-GTTGTTGCTCCAAGTATC-3'), M2S31N (5'-GTTGTTGCTGCAACA TC-3'), or M2del29-31 (5'-GTTGTTATCATTTGGGATCTTGC-3'); the back-to-back primers M2HATMR (5'-CACCAGTGAAGTGGCGACAGT TGAGTAGATCGCCAGAATGCACCTGAATCGTTGCATCTGC-3') and M2HATM (5'-CTTTTGGTCTCCCTGGGGGAATCAGTTTCTGGATGGA TCGTCTTTTTTCAAATGC-3') or M2NATMR (5'-GCTTAGTATCAATTG TATTCCATTTATGATTGATATCCAAATGCTGTCACTTGAATCGTTGC ATCTGC-3') or M2NATM (5'-ATTATAGGAGTCGTAATGTGTATCTCAG GGATTACCATAATAGATCGTCTTTTTTCAAATGC-3'); and the back-to-back primers UM772R (5'-TTGCATCTGCACCCCATTCG-3') and UMstop773 (5'-CGATTCAAGTGACTGATGAGTTGTTGC-3').

The PCR products were phosphorylated, self-ligated, propagated in *Escherichia coli* strain DH5 $\alpha$ , digested with *Bsm*BI, and cloned into the *Bsm*BI sites of the pHH21 vector. The resulting constructs were designated pPolIM2V27T, pPolIM2A30P, pPolIM2S31N, pPolIM2del29-31, pPolIM2HATM, pPolIM2NATM, and pPolIM2M2TMCYT. All of the constructs were sequenced to ensure that unwanted mutations were not present. The plasmids for the expression of the HA (pEWSN-HA), NP (pCAGGS-WSN-NP0/14), NA (pCAGGS-WNA15), and M1 (pCAGGS-WSN-M1-2/1) proteins of A/WSN/33 (H1N1) (WSN) virus and the M2 (pEP24c), NS2 (pCANS2), PB1 (pcDNA774), PB2 (pcDNA762), and PA (pcDNA787) of A/Puerto Rico/8/34 (H1N1) virus were described in a previous report (27).

**Plasmid-driven reverse genetics.** Transfectant viruses were generated as reported earlier (27). Briefly, 17 plasmids (eight PolI constructs for eight RNA segments and nine protein expression constructs for nine structural proteins) were mixed with transfection reagent (2  $\mu$ l of Trans IT LT-1 [Panvera, Madison, Wis.] per  $\mu$ g of DNA), incubated at room temperature for 15 min, and added to  $10^6$  293T cells. Six hours later, the DNA-transfection reagent mixture was replaced with Opti-MEM (Gibco-BRL) containing 0.3% bovine serum albumin and 0.01% FCS. Forty-eight hours later, viruses in the supernatant were plaque purified in MDCK cells once and then inoculated into MDCK cells for the production of stock virus. The M genes of transfectant viruses were sequenced to confirm the origin of the gene and the presence of the intended mutations and to ensure that no unwanted mutations were present. In all experiments, the transfectant viruses contained only the M gene from Udorn virus and the remaining genes from WSN virus.

**Replicative properties of transfectant viruses.** MDCK cells in duplicate wells of 24-well plates were infected with wild-type and mutant viruses, overlaid with MEM containing 0.5  $\mu$ g of trypsin per ml, and incubated at 37°C. At different times, supernatants were assayed for infectious virus in plaque assays on MDCK cells.

To investigate the amantadine sensitivity of mutant viruses, we titrated them in MDCK cells in the presence of different concentrations of the drug.

**M2 incorporation into virions.** Transfectant viruses were grown in MDCK cells containing 0.5  $\mu$ g of trypsin per ml and purified by centrifugation through six-step sucrose gradients (20, 30, 35, 40, 45, and 50%) for 2.5 h at 50,000  $\times$  g at 4°C. Fractions (0.3 ml each) were then collected through a hole pierced in the bottom of the tube and assayed by hemagglutination for the presence of virus. The fractions that contained virus were pooled and spun down at 50,000  $\times$  g for 1 h at 4°C, resuspended in phosphate-buffered saline (PBS), and stored in aliquots at -80°C. Purified virus was resuspended in lysis buffer (0.6 M KCl, 50 mM Tris-HCl [pH 7.5], 0.5% Triton X-100). The viral lysates were placed on sodium dodecyl sulfate (SDS)-15% polyacrylamide gels, which were then electrotransferred to a polyvinylidene difluoride membrane, which was blocked overnight at 4°C with 5% skim milk in PBS and incubated with the 14C2 anti-M2 monoclonal antibody (kindly provided by R. Lamb) and anti-WSN-NP monoclonal antibody for 1 h at room temperature. The membrane was washed three times with PBS containing 0.05% Tween 20. Bound antibodies were detected with a Vectastain ABC kit (Vector) and the Western immunoblot ECL system (Amersham). Signal intensities were quantified with an Alpha Imager 2000 (Alpha Innotech Corporation).

**Kinetics of viral protein synthesis.** MDCK cells were infected with wild-type or mutant viruses at a multiplicity of infection (MOI) of 1 PFU per cell. At different times, the infected cells were pulse labeled for 20 min with 50  $\mu$ Ci of [<sup>35</sup>S]methionine (ICN, Irvine, Calif.) per ml. Approximately  $10^5$  cells were lysed in 0.3 ml of radioimmunoprecipitation assay buffer (50 mM Tris-HCl [pH 7.6], 0.6 M KCl, 0.5% Triton X-100, 1 mM phenylmethylsulfonyl fluoride). The cell lysates were electrophoresed on SDS-15% polyacrylamide gels.

**Experimental infection.** Five-week-old female BALB/c mice, anesthetized with isoflurane, were infected intranasally with 50  $\mu$ l ( $5.0 \times 10^3$  PFU) of virus. Virus titers in organs were determined 3 days after infection with MDCK cells, as described (3).

## RESULTS

**Generation of influenza A viruses containing mutations in M2 protein.** The TM domain of the M2 protein possesses an  $\alpha$ -helical structure (10, 35, 44). Mutations at residues V-27, A-30, S-31, G-34, and L-38, all of which are located on the same face of the  $\alpha$ -helix, alter the properties of the M2 ion channel (14, 32, 49). To determine the role of the ion channel activity of M2 in viral replication, we initially constructed four plasmids and used them to generate mutant viruses with changes in the M2 TM domain (Fig. 1). The whole-cell currents of the mutant proteins, expressed in oocytes of *Xenopus laevis*, were measured by Holsinger et al. (18), using a two-electrode voltage clamp procedure. Two mutants, M2A30P

TABLE 1. Virus titers in the supernatant of 293T cells after plasmid transfection<sup>a</sup>

Virus	Titer (PFU/ml)
Wild type	$1.9 \times 10^5$
M2V27T	$6.0 \times 10^5$
M2A30P	$1.1 \times 10^6$
M2S31N	$1.2 \times 10^6$
M2del29-31	$1.7 \times 10^6$
M2HATM	$2.2 \times 10^4$
M2NATM	$2.2 \times 10^3$
$\Delta$ M2TMCYT	$1.4 \times 10^4$

<sup>a</sup> 293T cells were transfected with eight plasmids for the production of A/WSN/33 vRNA (excluding the M gene, which was derived from A/Udorn/72 virus) and nine protein expression plasmids, as described in Materials and Methods. At 48 h posttransfection, we titrated virus in the supernatant of 293T cell cultures using MDCK cells.

and M2del29-31, had no functional ion channel activity at either neutral or low pH. M2V27T and M2S31N, which showed ion channel activity at low pH (18), were used as positive controls.

To generate mutant viruses by plasmid-driven reverse genetics (27), we transfected 293T cells with nine protein expression plasmids and eight that directed the production of rRNA segments encoding all WSN viral genes except the M gene, which was derived from Udorn virus (wild type). The corresponding transfectant viruses were designated M2V27T, M2A30P, M2S31N, M2del29-31, and WSN-UdM (for the virus containing the parental Udorn M gene).

To determine the efficiency of virus generation, we titrated viruses in the culture supernatant of 293T cells at 48 h posttransfection with MDCK cells. As shown in Table 1, more than  $10^5$  transfectant viruses with the wild-type or mutant M gene were present. Thus, all viruses bearing M2 mutations and the virus possessing the wild-type Udorn M gene were generated with similar efficiencies. The transfectant viruses were plaque purified once in MDCK cells and then inoculated into MDCK cells to make virus stocks. The stability of the introduced mutations was analyzed by sequencing the M gene segments of the transfectant viruses after 10 passages in MDCK cells. No revertants were found (data not shown).

#### Growth properties of M2 mutant viruses in tissue culture.

We next compared the growth properties of M2 ion channel mutants and wild-type WSN-UdM virus in MDCK cells (Fig. 2). Cells were infected at an MOI of 0.001, and yields of virus in the culture supernatant were determined at different times postinfection at 37°C. The mutant viruses did not differ appreciably from the wild-type WSN-UdM virus in either growth rate (Fig. 2) or the size of plaques after 48 h of growth (1.5 mm in diameter).

To assess the amantadine sensitivity of these viruses, the M2 mutant and wild-type WSN-UdM viruses were grown in MDCK cells in the presence of different concentrations of amantadine. In cell culture, amantadine produces two discrete concentration-dependent inhibitory actions against viral replication. A nonspecific action at concentrations of  $>50 \mu\text{M}$ , resulting from an increase in the pH of endosomes, inhibits activation of HA membrane fusion activity involved in endocytosis (7), whereas at lower concentrations, 0.1 to  $5 \mu\text{M}$ , the drug selectively inhibits viral replication (2). As shown in Fig. 3, amantadine markedly reduced the yield of wild-type WSN-




FIG. 2. Growth curves of M2 mutant and wild-type WSN-UdM viruses. MDCK cells were infected with virus at an MOI of 0.001. At the indicated times after infection, the virus titer in the supernatant was determined. The values are means of triplicate experiments. The standard deviation (SD) is less than 0.59 for each sample.  $\square$ , M2V27T;  $\blacksquare$ , M2A30P; +, M2S31N;  $\triangle$ , M2del29-31;  $\circ$ , wild type.

UdM virus as well as the size of plaques (data not shown) at each of the three test concentrations. By contrast, at  $5 \mu\text{M}$  amantadine, the replication of M2 mutant viruses was either not affected or inhibited only slightly. Substantial inhibition due to the drug's nonspecific activity was seen at  $50 \mu\text{M}$ . Thus, all of our M2 mutants were more resistant to amantadine than the wild-type virus.

**Generation of transfectant viruses in which M2 TM domain was replaced with that from HA or NA.** Although the M2A30P and M2del29-31 mutants do not have functional ion channel activity (which was shown by Holsinger et al. [18] using a




FIG. 3. Amantadine sensitivity of M2 ion channel mutants. The mutant and wild-type WSN-UdM viruses were tested for plaque-forming capacity in MDCK cells in the presence of different concentrations of amantadine. Experiments were performed three times, with the results reported as means  $\pm$  SD.  $\blacksquare$ , M2V27T;  $\square$ , M2A30P;  $\bullet$ , M2S31N;  $\triangle$ , M2del29-31;  $\blacktriangle$ , wild type.




FIG. 4. Schematic diagram of the chimeric M2 mutants and the M2 mutant lacking the TM and cytoplasmic domains. Each chimeric mutant was constructed by replacing the TM domain of M2 with that of the HA or NA, while  $\Delta$ M2TMCYT was constructed by introducing two stop codons at the 3' end of the M1 ORF, resulting in a mutant lacking both the TM and cytoplasmic domains.

two-electrode voltage clamp procedure), they both replicated as well as the wild-type virus in MDCK cells (Fig. 2). However, we could not rule out the possibility of low-level ion channel activity below the sensitivity range of the assay. For this reason, we attempted to generate chimeric mutant viruses in which the M2 TM domain was replaced with that from the HA or NA of the A/WSN/33 virus (Fig. 4). When we assayed the supernatant of 293T cells transfected with plasmids for virus production, the chimeric mutants M2HATM and M2NATM were each viable, but their titers were more than 10-fold lower than that of the wild-type WSN-UdM titer (Table 1). The mutants also produced small plaques (1.0 mm in diameter) after 48 h of growth. Thus, influenza A virus can replicate without the M2 TM domain in cell culture.

**Generation of transfectant  $\Delta$ M2TMCYT virus lacking M2 TM and cytoplasmic domains.** Although the M2HATM and M2NATM viruses lack the M2 TM domain, their M2 proteins are membrane anchored. Thus, we conducted a more rigorous test of the requirement for M2 ion channel activity in influenza A virus replication. By constructing a mutant M gene possessing two stop codons at the 3' end of the M1 open reading frame (ORF), we attempted to produce a mutant virus with an M gene that encodes intact M1 protein and a truncated M2 corresponding to the ectodomain (23 amino acids), but lacking both a TM domain and a cytoplasmic tail (Fig. 4). The resultant virus,  $\Delta$ M2TMCYT, was viable (titer of  $1.4 \times 10^4$  PFU per ml of supernatant from 293T cell cultures transfected with plasmids for virus production [Table 1]) and produced pinpoint plaques ( $\sim 0.5$  mm in diameter). The titer of the stock virus was  $1 \times 10^4$  PFU per ml.

**Growth properties of M2HATM and  $\Delta$ M2TMCYT viruses in cell culture.** MDCK cells were infected with M2HATM at an MOI of 0.001 PFU per cell and with  $\Delta$ M2TMCYT at an MOI of 0.01 PFU per cell and incubated at 37°C. Although M2HATM produced a lower titer than the wild-type WSN-UdM virus at 12 and 24 h postinfection, its maximum titer at 36 h was almost the same as that of the wild-type virus (Fig. 5).




FIG. 5. Growth curves of M2HATM (□) and wild-type (●) WSN-UdM viruses. MDCK cells were infected with virus at an MOI of 0.001. At the indicated times after infection, the virus titer in the supernatant was determined. The values are means of triplicate experiments. The SD is less than 0.42 for each sample.

By contrast,  $\Delta$ M2TMCYT grew very slowly, reaching its maximum titer at 108 h postinfection (Fig. 6A). Interestingly, at 33°C, this mutant attained a titer of nearly  $10^6$  PFU per ml, equivalent to that of the wild-type virus (Fig. 6B), although its growth was substantially slower. These results indicate that influenza A virus can undergo multiple cycles of replication without the M2 TM and cytoplasmic domains, although these domains are both important for efficient viral replication.

**Incorporation of mutant M2 molecules into virions.** Conceivably, the M2 point and chimeric mutants possessed some residual ion channel activity, so that increased incorporation of the M2 protein into virions could compensate for any defect in this function. We therefore compared the efficiency of incorporation of the wild-type and mutant M2s into influenza virions by Western blot analysis after standardization based on the intensity of NP expression (Fig. 7). Virion incorporation of M2del29-31 and M2HATM M2 proteins was slightly reduced compared with the wild-type protein. The band detected slightly below the M2 protein of the wild-type virus is probably a proteolytically cleaved form of M2, as reported by others (51). An additional band below the NP protein, which was reactive with anti-NP but not anti-M2 antibody, is a cleavage product of NP (53). Together, these results demonstrate that increased incorporation of M2 protein into virions probably does not compensate for defective M2 ion channel activity.

**Kinetics of viral protein synthesis in mutant and wild-type virus-infected cells.** To determine whether the lack of M2 ion channel activity, as detected with the *in vitro* assay, affects the kinetics of viral replication, we examined the kinetics of viral protein production in MDCK cells that were infected with mutant or wild-type viruses. Similar results were obtained for the A30P, del29-31, HATM, and wild-type WSN-UdM viruses at 2, 4, 6, and 8 h postinfection (data not shown).

**Replication of M2 mutant viruses in mice.** To validate our *in vitro* test results in an animal model, we infected mice with each of our six mutant viruses (Table 2). M2A30P virus repli-




FIG. 6. Growth curves of  $\Delta$ M2MTCYT ( $\square$ ) and wild-type ( $\blacklozenge$ ) WSN-UdM viruses. MDCK cells were infected with virus at an MOI of 0.01 and incubated at 37°C (A) or 33°C (B). At the indicated times after infection, the virus titer in the supernatant was determined. The values are means of triplicate experiments. The SD is less than 0.40 for each sample.

cated in the lungs as well as the wild-type WSN-UdM and control M2V27T and M2S31N mutants, while replication of M2del29-31 virus in this organ was more than 10-fold lower. By contrast, neither the M2A30P nor the M2del29-31 virus was found in nasal turbinates from any of the infected mice. M2HATM and  $\Delta$ M2MTCYT viruses were not recovered from either the lungs or the nasal turbinates. These results establish that M2 ion channel activity is necessary for efficient influenza A virus replication in vivo.

## DISCUSSION

We used a new reverse-genetics system (27) to generate transfectant influenza A viruses with changes in the M2 TM




FIG. 7. Incorporation of M2 mutants into influenza virions. Purified viruses were lysed in sample buffer. Viral proteins were treated with 2-mercaptoethanol, separated by SDS-15% PAGE, transferred to a polyvinylidene difluoride membrane, and detected with the 14C2 anti-M2 monoclonal antibody and anti-WSN NP monoclonal antibody. Molecular masses of the marker proteins are shown on the left (in kilodaltons [K]).

domain sufficient to block ion channel activity according to in vitro assays (18). Despite this functional defect, all of the mutant viruses replicated as efficiently as the wild-type WSN-UdM virus in cell culture, although we could not rule out the possibility of residual ion channel activity adequate to support viral replication. Experiments in which the TM domain of the M2 protein was replaced with that from the HA (M2HATM) or NA (M2NATM) or was completely deleted together with the cytoplasmic domain ( $\Delta$ M2MTCYT) demonstrated that influenza A virus can undergo multiple cycles of replication in cell culture without M2 ion channel activity. However, the M2HATM and  $\Delta$ M2MTCYT viruses did not replicate in mice.

TABLE 2. Replication of M2 mutants in mice<sup>a</sup>

Virus	Mean titer (log <sub>10</sub> PFU/g) $\pm$ SD	
	Nasal turbinate	Lung
Wild type	3.9 $\pm$ 0.5	6.8 $\pm$ 0.3
M2V27T	4.3 $\pm$ 0.7	7.3 $\pm$ 0.3
M2A30P	NR <sup>b</sup>	6.8 $\pm$ 0.1
M2S31N	4.3 $\pm$ 0.4	7.0 $\pm$ 0.2
M2del29-31	NR	5.6 $\pm$ 0.1
M2HATM	NR	NR
$\Delta$ M2MTCYT <sup>c</sup>	NR	NR

<sup>a</sup> Five-week-old female BALB/c mice ( $n = 4$ ), anesthetized with isoflurane, were infected intranasally with 50  $\mu$ l of virus ( $5 \times 10^3$  PFU). Virus titers in organs were determined 3 days after infection with MDCK cells.

<sup>b</sup> NR, virus not recovered from any of the infected mice (less than  $10^2$  PFU/g).

<sup>c</sup> Mice were infected intranasally with 50  $\mu$ l of virus ( $7 \times 10^2$  PFU).

Since these mutant viruses grow substantially more slowly than the wild-type virus, they may be rapidly eliminated from the organs by host defense mechanisms, including the immune system. Thus, these results indicate that ion channel activity promotes efficient viral replication.

The M2 ectodomain is thought to be involved in the incorporation of M2 protein into virions (30). Moreover, deletion of 5 or 10 amino acids from the M2 cytoplasmic tail abrogates viral replication (4), possibly through adverse effects on ion channel activity (48) or perhaps by abolishing the protein's interaction with other viral components, including M1 protein (52). Thus, the greater attenuation in cell culture of  $\Delta$ M2TMCYT than of M2HATM suggests a requirement for both the TM and cytoplasmic domains of M2, and perhaps the ectodomain (30), to achieve maximally efficient viral replication.

M2 ion channel activity is believed to function at an early stage in the viral life cycle, between the steps of host cell penetration and uncoating of viral RNA. Zhirnov (54) reported that low pH induces the dissociation of M1 protein from viral RNPs *in vitro*. This observation led others to suggest that the introduction of protons into the interior of virions through M2 ion channel activity in the endosomes is responsible for M1 dissociation from RNP (16). If so, how could mutants with defects in ion channel activity replicate at all? Immunoelectron microscopy of the HA protein in virosomes exposed to low pH demonstrated that, in the absence of target membranes, the N-terminal fusion peptide of the HA2 subunit is inserted into the same membrane site where HA is anchored (50). Therefore, the fusion peptide of the HA might be inserted into the viral envelope, forming pores in the viral membrane that permit the flow of protons from the endosome into the virus's interior, leading to disruption of RNP-M1 interaction and hence to appreciable viral replication.

What is the origin of the M2 ion channel in influenza A virus? M2 ion channel activity was originally discovered in studies of the FPV Rostock strain (43), which has an intracellularly cleavable HA (29, 43, 46). In this strain, the HA undergoes a low-pH-induced conformational change in the *trans*-Golgi network in the absence of M2 ion channel activity, which raises the pH in this compartment. Hence, in the past, influenza A viruses may have harbored an M2 protein that promoted an increase in the pH of the *trans*-Golgi network, to a level that prevents conformational changes in the intracellularly cleavable HA. As influenza A viruses without intracellularly cleavable HAs began to appear, there was less selective pressure to maintain high ion channel activity associated with the M2 protein. Although decreased, this ion channel activity may have been sufficient to permit M1 to dissociate from RNP. In fact, ion channel activity differs markedly among the M2 proteins of currently recognized viruses. For example, to display the same ion channel activity as FPV Rostock virus (containing intracellularly cleavable HA), fivefold more M2 protein from human Udorn virus (containing intracellularly uncleavable HA) is needed (46). Conversely, the HAs of some influenza A viruses have changed from intracellularly uncleavable to cleavable during replication in chickens (19, 20, 22), suggesting that M2 protein with limited ion channel activity can acquire greater activity once a switch to intracellularly cleavable HA has occurred.

The M2HATM virus, although replicating reasonably well in cell culture, was highly attenuated in mice, raising the possibility of its use in the production of live vaccines. Cold-adapted live vaccines, now in clinical trials (25), hold considerable promise for use in the general population (38, 39, 40). The major concern is that the limited number of attenuating mutations in such vaccines (6, 17) could permit the generation of revertant viruses. Abolishing M2 ion channel activity, for example, by replacing the M2 TM domain with that from the HA, would greatly reduce the likelihood of the emergence of revertant viruses. Thus, by using the reverse-genetics system described in this report, one could generate influenza viruses with modified viral genes, as a first step in the production of safe live influenza vaccines.

To date, five viral proteins have been reported to act as ion channels: M2 of influenza A virus, NB of influenza B virus, Vpu and Vpr of human immunodeficiency virus type 1 (HIV-1), and Kcv of chlorella virus (12, 31, 32, 33, 37, 43, 44, 45). Since the replication strategies of influenza type A and B viruses are very similar, NB ion channel activity is also thought to play a role at an early stage of the viral life cycle, although this protein still lacks a demonstrated function in viral replication. Although the Vpu gene of HIV-1 can be deleted without completely abrogating HIV-1 replication *in vitro* (5, 23, 41, 42), the Vpu protein enhances the release of virus particles from cells (36, 41, 47). Vpr, another auxiliary HIV-1 protein, plays an important role in viral replication (8). Chlorella virus PBCV-1 encodes a functional K<sup>+</sup> channel protein, Kcv, which is important in the virus life cycle (33). On balance, the available data indicate that viral protein ion channel activities are integral parts of the viral life cycle and promote efficient viral replication.

#### ACKNOWLEDGMENTS

We thank Krisna Wells and Martha McGregor for excellent technical assistance, John Gilbert for editing the manuscript, and Robert Lamb for providing anti-M2 monoclonal antibody 14C2. We also thank John Skehel for helpful discussions. Automated sequencing was performed at the University of Wisconsin-Madison Biotechnology Center.

Support for this work was provided by NIAID Public Health Service research grants. T.W. is the recipient of a research fellowship from the Japan Society for the Promotion of Science for Young Scientists. S.W. is the recipient of a Japan Society for Promotion of Science postdoctoral fellowship for research abroad.

#### REFERENCES

1. Alberts, B., D. Bray, J. Lewis, M. Raff, K. Roberts, and J. D. Watson (ed.). 1994. *Molecular biology of the cell*. Garland Publishing, Inc., New York, N.Y.
2. Appleyard, G. 1977. Amantadine-resistance as a genetic marker for influenza viruses. *J. Gen. Virol.* **36**:249–255.
3. Bilsel, P., M. R. Castrucci, and Y. Kawaoka. 1993. Mutations in the cytoplasmic tail of influenza A virus neuraminidase affect incorporation into virions. *J. Virol.* **67**:6762–6767.
4. Castrucci, M. R., and Y. Kawaoka. 1995. Reverse genetics system for generation of an influenza A virus mutant containing a deletion of the carboxyl-terminal residue of M2 protein. *J. Virol.* **69**:2725–2728.
5. Cohen, E. A., E. F. Terwilliger, J. G. Sodroski, and W. A. Haseltine. 1988. Identification of a protein encoded by the vpu gene of HIV-1. *Nature* **334**:532–534.
6. Cox, N. J., F. Kitame, A. P. Kendal, H. F. Maassab, and C. Naeve. 1988. Identification of sequence changes in the cold-adapted, live attenuated influenza vaccine strain, A/Ann Arbor/6/60 (H2N2). *Virology* **167**:554–567.
7. Daniels, R. S., J. C. Downie, A. J. Hay, M. Knossow, J. J. Skehel, M. L. Wang, and D. C. Wiley. 1985. Fusion mutants of the influenza virus hemagglutinin glycoprotein. *Cell* **40**:431–439.
8. Dederá, D., W. Hu, H. Vander Heyden, and L. Ratner. 1989. Viral protein R

- of human immunodeficiency virus types 1 and 2 is dispensable for replication and cytopathogenicity in lymphoid cells. *J. Virol.* **63**:3205–3208.
9. **DuBridge, R. B., P. Tang, H. C. Hsia, P. M. Leong, J. H. Miller, and M. P. Calos.** 1987. Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. *Mol. Cell. Biol.* **7**:379–387.
  10. **Duff, K. C., and R. H. Ashley.** 1992. The transmembrane domain of influenza A M2 protein forms amantadine-sensitive proton channels in planar lipid bilayers. *Virology* **190**:485–489.
  11. **Duff, K. C., S. M. Kelly, N. C. Price, and J. P. Bradshaw.** 1992. The secondary structure of influenza A M2 transmembrane domain. *FEBS Lett.* **311**:256–258.
  12. **Ewart, G. D., T. Sutherland, P. W. Gage, and G. B. Cox.** 1996. The Vpu protein of human immunodeficiency virus type 1 forms cation-selective ion channels. *J. Virol.* **70**:7108–7115.
  13. **Fodor, E., L. Devenish, O. G. Engelhardt, P. Palese, G. G. Brownlee, and A. Garcia-Sastre.** 1999. Rescue of influenza A virus from recombinant DNA. *J. Virol.* **73**:9679–9682.
  14. **Grambas, S., M. S. Bennett, and A. J. Hay.** 1992. Influence of amantadine resistance mutations on the pH regulatory function of the M2 protein of influenza A viruses. *Virology* **190**:541–549.
  15. **Hay, A. J., A. J. Wolstenholme, J. J. Skehel, and M. H. Smith.** 1985. The molecular basis of the specific anti-influenza action of amantadine. *EMBO J.* **4**:3021–3024.
  16. **Helenius, A.** 1992. Unpacking the incoming influenza virus. *Cell* **69**:577–578.
  17. **Herlocher, M. L., H. F. Maassab, and R. G. Webster.** 1993. Molecular and biological changes in the cold-adapted “master strain” A/AA/6/60 (H2N2) influenza virus. *Proc. Natl. Acad. Sci. USA* **90**:6032–6036.
  18. **Holsinger, L. J., D. Nichani, L. H. Pinto, and R. A. Lamb.** 1994. Influenza A virus M2 ion channel protein: a structure-function analysis. *J. Virol.* **68**:1551–1563.
  19. **Horimoto, T., and Y. Kawaoka.** 1995. Molecular changes in virulent mutants arising from avirulent avian influenza viruses during replication in 14-day-old embryonated eggs. *Virology* **206**:755–759.
  20. **Horimoto, T., E. Rivera, J. Pearson, D. Sanne, S. Krauss, Y. Kawaoka, and R. G. Webster.** 1995. Origin and molecular changes associated with emergence of a highly pathogenic H5N2 influenza virus in Mexico. *Virology* **213**:223–230.
  21. **Katz, J. M., M. Wang, and R. G. Webster.** 1990. Direct sequencing of the hemagglutinin gene of influenza (H3N2) virus in original clinical samples reveals sequence identity with mammalian-cell-grown virus. *J. Virol.* **64**:1808–1811.
  22. **Kawaoka, Y., C. W. Naeve, and R. G. Webster.** 1984. Is virulence of H5N2 influenza viruses in chickens associated with loss of carbohydrate from the hemagglutinin? *Virology* **139**:303–316.
  23. **Klimkait, T., K. Strebel, M. D. Hoggan, M. A. Martin, and J. M. Orenstein.** 1990. The human immunodeficiency virus type 1-specific protein Vpu is required for efficient virus maturation and release. *J. Virol.* **64**:621–629.
  24. **Lamb, R. A., and R. A. Krug.** 1996. Orthomyxoviridae: the viruses and their replication, p. 1353–1395. *In* B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), *Fields virology*, 3rd ed. Lippincott-Raven Publishers, Philadelphia, Pa.
  25. **Maassab, H. F., and M. L. Bryant.** 1999. The development of live attenuated cold-adapted influenza virus vaccine for humans. *Rev. Med. Virol.* **9**:237–244.
  26. **Martin, K., and A. Helenius.** 1991. Nuclear transport of influenza virus ribonucleoproteins: The viral matrix protein (M1) promotes export and inhibits import. *Cell* **67**:117–130.
  27. **Neumann, G., T. Watanabe, H. Ito, S. Watanabe, H. Goto, P. Gao, M. Hughes, D. R. Perez, R. Donis, E. Hoffmann, G. Hobom, and Y. Kawaoka.** 1999. Generation of influenza A viruses entirely from cloned cDNAs. *Proc. Natl. Acad. Sci. USA* **96**:9345–9350.
  28. **Ochman, H., A. S. Gerber, and D. L. Hartl.** 1988. Genetics applications of an inverse polymerase chain reaction. *Genetics* **120**:621–623.
  29. **Ohuchi, M., A. Cramer, M. Vey, R. Ohuchi, W. Garten, and H.-D. Klenk.** 1994. Rescue of vector-expressed fowl plague virus hemagglutinin in biologically active form by acid-tropic agents and coexpressed M2 protein. *J. Virol.* **68**:920–926.
  30. **Park, E. K., M. R. Castrucci, A. Portner, and Y. Kawaoka.** 1998. The M2 ectodomain is important for its incorporation into influenza A virions. *J. Virol.* **72**:2449–2455.
  31. **Piller, S. C., G. D. Ewart, A. Premkumar, G. B. Cox, and P. W. Gage.** 1996. Vpr protein of human immunodeficiency virus type 1 forms cation-selective channels in planar lipid bilayers. *Proc. Natl. Acad. Sci. USA* **93**:111–115.
  32. **Pinto, L. H., L. J. Holsinger, and R. A. Lamb.** 1992. Influenza A virus M2 protein has ion channel activity. *Cell* **69**:517–528.
  33. **Plugge, B., S. Gazzarrini, M. Nelson, R. Cerana, J. L. Van Etten, C. Derst, D. DiFrancesco, A. Moroni, and G. Thiel.** 2000. A potassium channel protein encoded by chlorella virus PBCV-1. *Science* **287**:1641–1644.
  34. **Roizman, B., and P. Palese.** 1996. Multiplication of viruses: an overview, p. 101–111. *In* B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), *Fields virology*, 3rd ed. Lippincott-Raven Publishers, Philadelphia, Pa.
  35. **Sansom, M. S. P., and I. D. Kerr.** 1993. Influenza virus M2 protein: A molecular modeling study of the ion channel. *Protein Eng.* **6**:65–74.
  36. **Schubert, U., K. A. Clouse, and K. Strebel.** 1995. Augmentation of virus secretion by the human immunodeficiency virus type 1 Vpu protein is cell type independent and occurs in cultured human primary macrophages and lymphocytes. *J. Virol.* **69**:7699–7711.
  37. **Schubert, U., A. V. Ferrer-Montiel, M. Oblatt-Montal, P. Henklein, K. Strebel, and M. Montal.** 1996. Identification of an ion channel activity of the Vpu transmembrane domain and its involvement in the regulation of virus release from HIV-1 infected cells. *FEBS Lett.* **398**:12–18.
  38. **Sears, S. D., M. L. Clements, R. F. Betts, H. F. Maassab, B. R. Murphy, and M. H. Snyder.** 1988. Comparison of live, attenuated H1N1 and H3N2 cold-adapted and avian-human influenza A reassortant viruses and inactivated virus vaccine in adults. *J. Infect. Dis.* **158**:1209–1219.
  39. **Steinhoff, M. C., N. A. Halsey, M. H. Wilson, B. A. Burns, R. K. Samorodin, L. F. Fries, B. R. Murphy, and M. L. Clements.** 1990. Comparison of live attenuated cold-adapted and avian-human influenza A/Bethesda/85 (H3N2) reassortant virus vaccines in infants and children. *J. Infect. Dis.* **162**:394–401.
  40. **Steinhoff, M. C., N. A. Halsey, L. F. Fries, M. H. Wilson, J. King, B. A. Burns, R. K. Samorodin, V. Perkis, B. R. Murphy, and M. L. Clements.** 1991. The A/Mallard/6750/78 avian-human, but not the A/Ann Arbor/6/60 cold-adapted, influenza A/Kawasaki/86 (H1N1) reassortant virus vaccine retains partial virulence for infants and children. *J. Infect. Dis.* **163**:1023–1028.
  41. **Strebel, K., T. Klimkait, and M. A. Martin.** 1988. A novel gene of HIV-1, VPU, and its 16-kilodalton product. *Science* **241**:1221–1223.
  42. **Strebel, K., T. Klimkait, F. Maldarelli, and M. A. Martin.** 1989. Molecular and biochemical analyses of human immunodeficiency virus type 1 Vpu protein. *J. Virol.* **63**:3784–3791.
  43. **Sugrue, R. J., G. Bahadur, M. C. Zambom, M. Hall-Smith, A. R. Douglas, and A. J. Hay.** 1990. Specific structure alteration of the influenza haemagglutinin by amantadine. *EMBO J.* **9**:3469–3476.
  44. **Sugrue, R. J., and A. J. Hay.** 1991. Structural characteristics of the M2 protein of the influenza A viruses: evidence that it forms a tetrameric channel. *Virology* **180**:617–624.
  45. **Sunstrom, N. A., L. S. Premkumar, A. Premkumar, G. Ewart, G. B. Cox, and P. W. Gage.** 1996. Ion channels formed by NB, an influenza B virus protein. *J. Membr. Biol.* **150**:127–132.
  46. **Takeuchi, K., and R. A. Lamb.** 1994. Influenza virus M2 protein ion channel activity stabilizes the native form of fowl plague virus hemagglutinin during intracellular transport. *J. Virol.* **68**:911–919.
  47. **Terwilliger, E. F., E. A. Cohen, Y. C. Lu, J. G. Sodroski, and W. A. Haseltine.** 1989. Functional role of human immunodeficiency virus type 1 vpu. *Proc. Natl. Acad. Sci. USA* **86**:5163–5167.
  48. **Tobler, K., M. L. Kelly, L. H. Pinto, and R. A. Lamb.** 1999. Effect of cytoplasmic tail truncations on the activity of the M2 ion channel of influenza A virus. *J. Virol.* **73**:9695–9701.
  49. **Wang, C., K. Takeuchi, L. H. Pinto, and R. A. Lamb.** 1993. The ion channel activity of influenza A virus protein: characterization of the amantadine block. *J. Virol.* **67**:5585–5594.
  50. **Wharton, S. A., L. J. Calder, R. W. H. Ruigrok, J. J. Skehel, D. A. Steinhauer, and D. C. Wiley.** 1995. Electron microscopy of antibody complexes of influenza virus hemagglutinin in the fusion pH conformation. *EMBO J.* **14**:240–246.
  51. **Zebedee, S. L., and R. A. Lamb.** 1988. Influenza virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions. *J. Virol.* **62**:2762–2772.
  52. **Zebedee, S. L., and R. A. Lamb.** 1989. Growth restriction of influenza A virus by M2 protein antibody is genetically linked to the M1 protein. *Proc. Natl. Acad. Sci. USA* **86**:1061–1065.
  53. **Zhirnov, O., and A. G. Bukrinskaya.** 1984. Nucleoproteins of animal influenza viruses, in contrast to those of human strains, are not cleaved in infected cells. *J. Gen. Virol.* **65**:1127–1134.
  54. **Zhirnov, O. P.** 1990. Solubilization of matrix protein M1/M from virions occurs at different pH for orthomyxo- and paramyxoviruses. *Virology* **176**:274–279.